Infrastructure for Formulary Optimization & Utilization Management

Formulary optimization requires documented P&T committee criteria for formulary additions, restrictions, and therapeutic substitutions—evaluation frameworks covering clinical evidence, cost-effectiveness thresholds, and safety profiles. These policies must be current and findable to provide the rule basis for the ML platform's recommendations. The formulary itself is explicitly documented, and P&T processes are formally governed. However, individualized clinical judgment for specific therapeutic equivalence decisions—and the economic criteria used to weigh formulary changes—remain less formally codified.

Formulary optimization requires systematic capture of medication utilization events—drug, quantity, cost, prescribing unit, and indication when available—through consistent workflows. CPOE and ADC logs provide this foundation automatically. P&T committee decisions, non-formulary exception approvals, and therapeutic substitution intervention outcomes must also be captured through template-driven documentation to enable the ML platform to correlate formulary policy changes with utilization shifts and cost outcomes.

Formulary optimization modeling requires consistent schema: drug records with NDC, formulary status, restriction tier, acquisition cost, therapeutic class, and clinical outcome linkage where available. All utilization records must reference the same drug taxonomy (NDC, RxNorm, therapeutic class hierarchy) to enable cross-drug comparison within therapeutic categories. Benchmark data from peer institutions and clinical evidence ratings must share compatible schema for the platform to produce cost-effectiveness analyses.

Formulary optimization requires API access to pharmacy utilization data, formulary management system, cost/financial data (acquisition cost, contract pricing), clinical outcomes where linked to medication therapy, and external benchmark databases. These API connections enable the ML platform to assemble the utilization-cost-outcome triad needed for formulary recommendations without manual data exports. The existing pharmacy system API infrastructure supports internal data access; external benchmark feeds extend it.

Formulary optimization logic and utilization benchmarks are updated on P&T committee cycles—typically monthly or quarterly—reflecting the governance rhythm of formulary management. Clinical evidence ratings for therapeutic equivalence are reviewed when new drugs are considered for formulary addition, not continuously. This scheduled periodic maintenance posture reflects the organizational reality that formulary decisions require committee deliberation, and the optimization platform's recommendation logic updates accordingly after committee decisions rather than in real-time.

Formulary optimization requires API-based connections between the pharmacy dispensing system, financial/cost database (acquisition costs, contract pricing), clinical outcomes data (where available), formulary management system, and external benchmark databases from GPO or peer institutions. These connections enable the platform to compute utilization patterns, cost implications, and outcome associations without manual data assembly by pharmacy analysts. The existing pharmacy-to-EHR integration provides the clinical data foundation.